STOCK TITAN

Kraig Biocraft Laboratories Meets its Target With Largest Ever Product Batch of BAM-1 Spider Silk - Surpassing Entire 2024 Output

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a significant production milestone in spider silk manufacturing. The company has completed its largest single batch of BAM-1 recombinant spider silk, surpassing its entire 2024 production output in just one production run in early 2025.

The achievement follows a record-breaking 2024, where the company produced more spider silk than all previous years combined. This expansion demonstrates Kraig Labs' ability to scale up commercial production of its revolutionary spider silk technology for applications in technical textiles, defense, and performance apparel industries.

According to COO Jon Rice, this milestone validates the company's robust spider silk production platform and its capability to deliver industrial-scale quantities of this advanced biomaterial. The company aims to meet what it perceives as substantial global demand for high-performance spider silk.

Kraig Biocraft Laboratories (OTCQB: KBLB) ha raggiunto un traguardo significativo nella produzione di seta di ragno. L'azienda ha completato il suo più grande lotto singolo di seta di ragno ricombinante BAM-1, superando l'intera produzione prevista per il 2024 in un'unica fase produttiva all'inizio del 2025.

Questo risultato segue un 2024 da record, in cui l'azienda ha prodotto più seta di ragno di tutti gli anni precedenti messi insieme. Questa espansione dimostra la capacità di Kraig Labs di aumentare la produzione commerciale della sua tecnologia rivoluzionaria della seta di ragno per applicazioni nei settori dei tessuti tecnici, della difesa e dell'abbigliamento performante.

Secondo il COO Jon Rice, questo traguardo convalida la robusta piattaforma di produzione di seta di ragno dell'azienda e la sua capacità di fornire quantità industriali di questo biomateriale avanzato. L'azienda mira a soddisfare quella che percepisce come una sostanziale domanda globale di seta di ragno ad alte prestazioni.

Kraig Biocraft Laboratories (OTCQB: KBLB) ha logrado un hito significativo en la fabricación de seda de araña. La compañía ha completado su mayor lote individual de seda de araña recombinante BAM-1, superando toda su producción prevista para 2024 en una sola corrida de producción a principios de 2025.

Este logro sigue a un 2024 récord, donde la empresa produjo más seda de araña que en todos los años anteriores combinados. Esta expansión demuestra la capacidad de Kraig Labs para escalar la producción comercial de su tecnología revolucionaria de seda de araña para aplicaciones en textiles técnicos, defensa y prendas de alto rendimiento.

Según el COO Jon Rice, este hito valida la robusta plataforma de producción de seda de araña de la empresa y su capacidad para entregar cantidades a escala industrial de este biomaterial avanzado. La compañía tiene como objetivo satisfacer lo que percibe como una demanda global sustancial de seda de araña de alto rendimiento.

Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미줄 제조에서 중요한 생산 이정표를 달성했습니다. 이 회사는 BAM-1 재조합 거미줄의 가장 큰 단일 배치를 완료하여 2024년 전체 생산량을 2025년 초 단 한 번의 생산 과정에서 초과했습니다.

이 성과는 2024년의 기록적인 결과에 이어져, 회사는 이전 모든 해를 합친 것보다 더 많은 거미줄을 생산했습니다. 이 확장은 Kraig Labs가 기술 섬유, 방위 및 성능 의류 산업을 위한 혁신적인 거미줄 기술의 상업 생산을 확장할 수 있는 능력을 보여줍니다.

COO Jon Rice에 따르면, 이 이정표는 회사의 강력한 거미줄 생산 플랫폼과 이 첨단 생체 재료의 산업 규모의 양을 제공할 수 있는 능력을 검증합니다. 회사는 고성능 거미줄에 대한 상당한 글로벌 수요를 충족하는 것을 목표로 하고 있습니다.

Kraig Biocraft Laboratories (OTCQB: KBLB) a atteint un jalon de production significatif dans la fabrication de soie d'araignée. L'entreprise a complété son plus grand lot unique de soie d'araignée recombinante BAM-1, dépassant l'ensemble de sa production prévue pour 2024 en une seule série de production au début de 2025.

Ce succès fait suite à une année 2024 record, où l'entreprise a produit plus de soie d'araignée que toutes les années précédentes réunies. Cette expansion démontre la capacité de Kraig Labs à augmenter la production commerciale de sa technologie révolutionnaire de soie d'araignée pour des applications dans les textiles techniques, la défense et les vêtements de performance.

Selon le COO Jon Rice, ce jalon valide la plateforme de production robuste de soie d'araignée de l'entreprise et sa capacité à fournir des quantités à l'échelle industrielle de ce biomatériau avancé. L'entreprise vise à répondre à ce qu'elle perçoit comme une demande mondiale substantielle pour de la soie d'araignée haute performance.

Kraig Biocraft Laboratories (OTCQB: KBLB) hat einen bedeutenden Produktionsmeilenstein in der Herstellung von Spinnenseide erreicht. Das Unternehmen hat seinen größten Einzelbatch von rekombinanter Spinnenseide BAM-1 abgeschlossen und damit die gesamte Produktionsmenge für 2024 in nur einem Produktionslauf Anfang 2025 übertroffen.

Dieser Erfolg folgt auf ein rekordverdächtiges Jahr 2024, in dem das Unternehmen mehr Spinnenseide produziert hat als in allen vorherigen Jahren zusammen. Diese Expansion zeigt die Fähigkeit von Kraig Labs, die kommerzielle Produktion seiner revolutionären Spinnenseidentechnologie für Anwendungen in technischen Textilien, Verteidigung und Leistungsbekleidung zu skalieren.

Laut COO Jon Rice bestätigt dieser Meilenstein die robuste Produktionsplattform des Unternehmens für Spinnenseide und seine Fähigkeit, industrielle Mengen dieses fortschrittlichen Biomaterials bereitzustellen. Das Unternehmen hat sich zum Ziel gesetzt, die als erheblich wahrgenommene globale Nachfrage nach leistungsstarker Spinnenseide zu decken.

Positive
  • Achieved largest single batch production of BAM-1 spider silk, exceeding entire 2024 output
  • Demonstrated successful scaling of industrial production capabilities
  • 2024 production exceeded all previous years combined
Negative
  • None.

ANN ARBOR, Mich., March 10, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a global leader in engineered spider silk technologies, is thrilled to announce that it has begun production of the largest single batch of BAM-1 recombinant spider silk in the Company's history. Last year, the Company publicly set a goal of exceeding all of 2024's production with a single production batch in 2025. Today, Kraig Labs announces it has far exceeded that goal and kept that promise.

BAM-1 Silkworms (1)

In 2024, Kraig Labs produced more spider silk than in all previous years combined. Following a record-breaking 2024, the Company is now surpassing that milestone with just a single production run in early 2025. This single production run is larger than the Company's entire output for the previous 12 months. This extraordinary expansion underscores the Company’s continued success in scaling up the commercial production of its revolutionary spider silk technology.

"Today, we are making history," said Jon Rice, Chief Operations Officer of Kraig Labs. "This production run is not just our largest to date—it is larger than everything we produced throughout all of 2024. This achievement demonstrates our ability to dramatically scale BAM-1 silk output, bringing us closer than ever to meeting what we see as an immense global demand for high-performance spider silk."

BAM-1 Silkworms (3)

The current BAM-1 silk production run is the latest in a series of breakthroughs that validate the Company's robust spider silk production platform and its ability to deliver industrial-scale quantities of its cutting-edge biomaterial. Kraig Labs remains committed to pushing the boundaries of advanced material science, leveraging its scalable production systems to create unprecedented opportunities in technical textiles, defense, and performance apparel industries.

"As we continue to ramp up production, this milestone is a clear testament to the dedication of our team and the scalability of our technology," said Rice. "We set out to revolutionize the performance materials market, and we are proving that spider silk is no longer a material of the future—it is here today and ready for commercialization."

With this historic production milestone, Kraig Labs is further solidifying its position as the industry leader in spider silk manufacturing. The Company looks forward to sharing further updates as it advances toward commercial deliveries and strategic partnerships.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a69e49e5-be00-4202-93df-13c1534fe33e
https://www.globenewswire.com/NewsRoom/AttachmentNg/9458782a-33b2-4b24-9c18-d7173edbeb37


FAQ

How much BAM-1 spider silk did KBLB produce in their latest batch compared to 2024?

The latest single production batch in early 2025 exceeded KBLB's entire production output for 2024.

What industries is KBLB targeting with their spider silk technology?

KBLB is targeting technical textiles, defense, and performance apparel industries.

What production milestone did KBLB achieve in 2024?

In 2024, KBLB produced more spider silk than all previous years combined.

How does this production milestone impact KBLB's commercialization plans?

The milestone demonstrates KBLB's ability to produce industrial-scale quantities, bringing them closer to commercial deliveries and strategic partnerships.
Kraig Biocraft Laboratories In

OTC:KBLB

KBLB Rankings

KBLB Latest News

KBLB Stock Data

96.98M
775.26M
25.21%
Specialty Chemicals
Basic Materials
Link
United States
Ann Arbor